[{"id":"28d28f42-9a11-470f-aad6-b354ed154518","acronym":"PULMO-01","url":"https://clinicaltrials.gov/study/NCT06879717","created_at":"2025-09-07T02:00:11.544Z","updated_at":"2025-09-07T02:00:11.544Z","phase":"Phase 1/2","brief_title":"A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients","source_id_and_acronym":"NCT06879717 - PULMO-01","lead_sponsor":"iOnctura","biomarkers":" IL7R","pipe":"","alterations":" ","tags":["IL7R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Jemperli (dostarlimab-gxly) • roginolisib (IOA-244)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 04/22/2025","start_date":" 04/22/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-05-13"},{"id":"9d2b54f0-0907-4b8a-b5db-69cd00d54eb2","acronym":"SWOG S1608","url":"https://clinicaltrials.gov/study/NCT03269669","created_at":"2021-01-29T07:15:29.475Z","updated_at":"2025-02-25T12:26:46.064Z","phase":"Phase 2","brief_title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","source_id_and_acronym":"NCT03269669 - SWOG S1608","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • prednisone • bendamustine • Ukoniq (umbralisib) • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 01/23/2018","start_date":" 01/23/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"9563a22f-1431-499b-ba51-cc38d3b74ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04345913","created_at":"2021-01-18T21:01:42.609Z","updated_at":"2025-02-25T13:40:07.851Z","phase":"Phase 1/2","brief_title":"Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT04345913","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PIK3CA • PGR • PTEN","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PIK3CA mutation","tags":["ER • PIK3CA • PGR • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-21"},{"id":"f5056d6b-3ffd-4e44-961f-b461e0552213","acronym":"A051902","url":"https://clinicaltrials.gov/study/NCT04803201","created_at":"2021-03-17T15:57:46.362Z","updated_at":"2025-02-25T14:15:53.168Z","phase":"Phase 2","brief_title":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT04803201 - A051902","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" TNFRSF8 expression","tags":["PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • azacitidine • cyclophosphamide • etoposide IV • Copiktra (duvelisib) • vincristine • prednisone • Onureg (azacitidine oral) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 10/08/2021","start_date":" 10/08/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-18"},{"id":"fe033f7e-24b3-4288-bdd8-92b0259dd61d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05010005","created_at":"2021-08-18T15:53:40.772Z","updated_at":"2025-02-25T15:27:02.226Z","phase":"Phase 1","brief_title":"A Study of Ruxolitinib and Duvelisib in People With Lymphoma","source_id_and_acronym":"NCT05010005","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD8","pipe":" | ","alterations":" CD8 positive","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • Copiktra (duvelisib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 08/12/2021","start_date":" 08/12/2021","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-10"},{"id":"56dc1b56-646f-4648-9e26-4b51bc644b50","acronym":"","url":"https://clinicaltrials.gov/study/NCT04317105","created_at":"2021-01-18T20:55:21.759Z","updated_at":"2025-02-25T16:37:48.003Z","phase":"Phase 1/2","brief_title":"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN","source_id_and_acronym":"NCT04317105","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation","tags":["PD-L1 • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Aliqopa (copanlisib) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 07/17/2020","start_date":" 07/17/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"aa4d2f71-0b09-413a-abc9-1d8702d772bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05065866","created_at":"2021-10-04T12:53:00.645Z","updated_at":"2025-02-25T16:45:37.143Z","phase":"Phase 1","brief_title":"Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy","source_id_and_acronym":"NCT05065866","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ALK • MYC • BCL2 • CD8 • TNFRSF8 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • MYC • BCL2 • CD8 • TNFRSF8 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Copiktra (duvelisib) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 11/18/2021","start_date":" 11/18/2021","primary_txt":" Primary completion: 01/02/2024","primary_completion_date":" 01/02/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-06"},{"id":"c392c236-bf01-4f33-b758-84c02e4596c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03939897","created_at":"2021-01-18T19:24:01.905Z","updated_at":"2025-02-25T16:52:29.645Z","phase":"Phase 1","brief_title":"Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer","source_id_and_acronym":"NCT03939897","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PIK3CA • PGR • PTEN","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PGR positive","tags":["HER-2 • ER • PIK3CA • PGR • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/17/2020","start_date":" 06/17/2020","primary_txt":" Primary completion: 06/22/2023","primary_completion_date":" 06/22/2023","study_txt":" Completion: 07/16/2025","study_completion_date":" 07/16/2025","last_update_posted":"2025-02-04"},{"id":"13809b89-05e8-41ef-8215-b7d1aaa392e9","acronym":"NCI-2018-01880","url":"https://clinicaltrials.gov/study/NCT03884998","created_at":"2021-01-18T19:08:46.177Z","updated_at":"2025-02-25T17:36:15.593Z","phase":"Phase 1","brief_title":"Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03884998 - NCI-2018-01880","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 02/26/2019","start_date":" 02/26/2019","primary_txt":" Primary completion: 07/16/2025","primary_completion_date":" 07/16/2025","study_txt":" Completion: 07/16/2025","study_completion_date":" 07/16/2025","last_update_posted":"2025-01-29"},{"id":"8f688b25-930e-42ca-9a40-fca5c6f5662a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04890236","created_at":"2021-05-18T12:01:56.234Z","updated_at":"2025-02-25T15:54:04.644Z","phase":"Phase 1","brief_title":"Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study","source_id_and_acronym":"NCT04890236","lead_sponsor":"Emory University","biomarkers":" CD27","pipe":"","alterations":" ","tags":["CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Copiktra (duvelisib) • Kymriah (tisagenlecleucel-T) • ETP-47187"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 01/13/2022","start_date":" 01/13/2022","primary_txt":" Primary completion: 03/20/2024","primary_completion_date":" 03/20/2024","study_txt":" Completion: 09/04/2024","study_completion_date":" 09/04/2024","last_update_posted":"2025-01-20"},{"id":"83a4cc91-840b-45a5-8084-819f697c1e10","acronym":"CA209-8LC","url":"https://clinicaltrials.gov/study/NCT03711058","created_at":"2021-01-18T18:11:36.282Z","updated_at":"2025-02-25T14:27:43.047Z","phase":"Phase 1/2","brief_title":"Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer","source_id_and_acronym":"NCT03711058 - CA209-8LC","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS wild-type • BRAF wild-type • NRAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • BRAF wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 01/17/2019","start_date":" 01/17/2019","primary_txt":" Primary completion: 06/14/2022","primary_completion_date":" 06/14/2022","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-01-13"},{"id":"51bc21f1-64c8-4e95-bcfa-4fdd977e48c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04572763","created_at":"2021-01-18T21:50:00.501Z","updated_at":"2025-02-25T17:24:50.909Z","phase":"Phase 1/2","brief_title":"Copanlisib Plus Venetoclax in R/R DLBCL","source_id_and_acronym":"NCT04572763","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" MYC translocation","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 09/08/2021","start_date":" 09/08/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-12-20"},{"id":"739a6ead-49a8-4524-b971-bdd0dec1f85b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05082025","created_at":"2021-10-18T12:53:16.001Z","updated_at":"2025-02-25T17:25:18.256Z","phase":"Phase 2","brief_title":"Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations","source_id_and_acronym":"NCT05082025","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PIK3CA • PGR • PTEN • PIK3R1 • PI3K","pipe":" | ","alterations":" ER positive • PIK3CA mutation • PTEN deletion","tags":["ER • PIK3CA • PGR • PTEN • PIK3R1 • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation • PTEN deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 09/27/2022","start_date":" 09/27/2022","primary_txt":" Primary completion: 10/29/2026","primary_completion_date":" 10/29/2026","study_txt":" Completion: 10/29/2026","study_completion_date":" 10/29/2026","last_update_posted":"2024-12-18"},{"id":"ed362182-add1-434a-b6df-44f932cad804","acronym":"","url":"https://clinicaltrials.gov/study/NCT02135133","created_at":"2021-01-18T09:54:33.334Z","updated_at":"2025-02-25T13:11:11.926Z","phase":"Phase 2","brief_title":"A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL","source_id_and_acronym":"NCT02135133","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CD19 • CCND1 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD19 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zydelig (idelalisib) • Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 10/06/2020","primary_completion_date":" 10/06/2020","study_txt":" Completion: 10/06/2020","study_completion_date":" 10/06/2020","last_update_posted":"2024-10-16"},{"id":"62fde8ea-b4f1-4e11-9442-c58db1f54a1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04688658","created_at":"2021-01-19T20:48:11.081Z","updated_at":"2025-02-25T14:29:48.942Z","phase":"Phase 1/2","brief_title":"Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma","source_id_and_acronym":"NCT04688658","lead_sponsor":"John Kirkwood","biomarkers":" BRAF • CD8","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • axitinib • Copiktra (duvelisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 07/21/2021","start_date":" 07/21/2021","primary_txt":" Primary completion: 02/22/2024","primary_completion_date":" 02/22/2024","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-08-08"},{"id":"98bf47af-2f07-41d0-8aba-0ad0045bf73a","acronym":"CHRONOS-1","url":"https://clinicaltrials.gov/study/NCT01660451","created_at":"2021-01-18T07:10:10.841Z","updated_at":"2025-02-25T17:20:13.895Z","phase":"Phase 2","brief_title":"Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas","source_id_and_acronym":"NCT01660451 - CHRONOS-1","lead_sponsor":"Bayer","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aliqopa (copanlisib)"],"overall_status":"Completed","enrollment":" Enrollment 227","initiation":"Initiation: 11/19/2012","start_date":" 11/19/2012","primary_txt":" Primary completion: 06/22/2016","primary_completion_date":" 06/22/2016","study_txt":" Completion: 05/18/2023","study_completion_date":" 05/18/2023","last_update_posted":"2024-07-17"},{"id":"1d394ddd-86a9-4b8f-a2a2-adf734a97239","acronym":"","url":"https://clinicaltrials.gov/study/NCT03502733","created_at":"2023-12-06T17:15:36.704Z","updated_at":"2024-07-02T16:34:25.709Z","phase":"Phase 1","brief_title":"Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma","source_id_and_acronym":"NCT03502733","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RAD51","pipe":"","alterations":" ","tags":["RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Aliqopa (copanlisib) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 08/14/2018","start_date":" 08/14/2018","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-14"},{"id":"413409a2-0792-4de1-a64e-d4d1801140e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03586661","created_at":"2021-01-18T17:38:28.376Z","updated_at":"2024-07-02T16:34:27.534Z","phase":"Phase 1","brief_title":"Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT03586661","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 04/29/2019","start_date":" 04/29/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-11"},{"id":"d7b63745-b754-4312-8d12-7caa21ac459b","acronym":"BGB-A317-3111-10188-101","url":"https://clinicaltrials.gov/study/NCT04282018","created_at":"2021-01-18T20:47:22.139Z","updated_at":"2024-07-02T16:34:37.351Z","phase":"Phase 1/2","brief_title":"Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab","source_id_and_acronym":"NCT04282018 - BGB-A317-3111-10188-101","lead_sponsor":"BeiGene","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Tevimbra (tislelizumab-jsgr) • Brukinsa (zanubrutinib) • BGB-10188"],"overall_status":"Recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 05/25/2020","start_date":" 05/25/2020","primary_txt":" Primary completion: 05/06/2025","primary_completion_date":" 05/06/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-07"},{"id":"597f3d3b-7b1b-4903-87c4-f3117fd83b5e","acronym":"topMIND","url":"https://clinicaltrials.gov/study/NCT04809467","created_at":"2021-03-22T11:52:17.035Z","updated_at":"2024-07-02T16:34:37.699Z","phase":"Phase 1/2","brief_title":"A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)","source_id_and_acronym":"NCT04809467 - topMIND","lead_sponsor":"Incyte Corporation","biomarkers":" BCL2 • CCND1 • BCL6","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e parsaclisib (INCB50465) • Monjuvi (tafasitamab-cxix)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/16/2021","start_date":" 09/16/2021","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-06-06"},{"id":"d2401e9e-4fcb-4143-a93d-a94dce3674a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04939272","created_at":"2021-06-25T22:54:05.033Z","updated_at":"2024-07-02T16:34:58.910Z","phase":"Phase 1/2","brief_title":"Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT04939272","lead_sponsor":"City of Hope Medical Center","biomarkers":" BCL2 • CD20 • CCND1 • PAX5 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • PAX5 overexpression","tags":["BCL2 • CD20 • CCND1 • PAX5 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • PAX5 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 06/29/2022","start_date":" 06/29/2022","primary_txt":" Primary completion: 11/23/2024","primary_completion_date":" 11/23/2024","study_txt":" Completion: 11/23/2024","study_completion_date":" 11/23/2024","last_update_posted":"2024-06-04"},{"id":"4aeeae3b-239d-409e-b580-694a2f0d8715","acronym":"NCI-2022-06209","url":"https://clinicaltrials.gov/study/NCT05490771","created_at":"2022-08-08T12:59:00.924Z","updated_at":"2024-07-02T16:35:01.772Z","phase":"Phase 2","brief_title":"Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)","source_id_and_acronym":"NCT05490771 - NCI-2022-06209","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 01/06/2021","primary_completion_date":" 01/06/2021","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-23"},{"id":"b82d5afc-83e5-4037-9280-7d0e4dfd7f17","acronym":"NCI10217","url":"https://clinicaltrials.gov/study/NCT03842228","created_at":"2021-01-18T18:58:03.649Z","updated_at":"2024-07-02T16:35:02.758Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations","source_id_and_acronym":"NCT03842228 - NCI10217","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA • BRCA1 • BRCA2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation • PALB2 mutation • CDK12 mutation • PIK3CA E545 • PIK3CA H1047 • BARD1 mutation • PIK3CA E542 • RAD51 mutation","tags":["PIK3CA • BRCA1 • BRCA2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation • PALB2 mutation • CDK12 mutation • PIK3CA E545 • PIK3CA H1047 • BARD1 mutation • PIK3CA E542 • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 11/21/2019","start_date":" 11/21/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-17"},{"id":"e704c4fd-c7ac-4597-8954-effccdbd050f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05949944","created_at":"2023-07-20T15:09:21.771Z","updated_at":"2024-07-02T16:35:02.840Z","phase":"Phase 1/2","brief_title":"Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT05949944","lead_sponsor":"Sun Yat-sen University","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 expression • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 expression • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Itari (linperlisib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/15/2023","start_date":" 08/15/2023","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-17"}]